Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Enzo Biochem Inc Announces Study In Scientific Journal Linking Idiopathic Pulmonary Fibrosis


Friday, 15 Nov 2013 08:30am EST 

Enzo Biochem Inc announced publication of a study in a scientific journal, Modern Pathology, a Nature Publishing Group publication, that shows a strong association of idiopathic pulmonary fibrosis (IPF), a pulmonary disease with 100% mortality within five years, with the presence of the herpesvirus saimiri virus, a virus native to squirrel monkeys. The discovery of the IPF`s origin is expected to result in a clinical diagnostic that could lead to screening and diagnosis, and perhaps result in potential treatment, for this fatal disease. The publication was authored by scientists from Enzo Biochem, Ohio State University, the Medical College of Wisconsin and Cornell University. The discovery is the subject of a patent application that is exclusively assigned to Enzo Biochem. Pulmonary fibrosis affects about one million people in the United States, of which IPF represents about 200,000 cases (20%). There is currently no effective way to diagnose IPF prior to the clinical manifestation of symptoms and treatments are largely ineffective. This new marker for IPF could address the urgent critical requirement for early diagnosis and screening of the pulmonary fibrosis population (over a million subjects). The goal of the study was to evaluate the role of the herpesviruses family in IPF. Researchers used 21 paraffin embedded lung biopsies from patients diagnosed with IPF, and 21 lung biopsies from age matched controls with pulmonary fibrosis that is not IPF. 

Company Quote

4.64
-0.07 -1.49%
25 Nov 2014